Julien Lefranc

#Medchem @merckgroup former @bayerpharma interested in #cancer #kinaseinhibitors #degraders only personal views Reviewer @drughunter

[AACR @AACR]

The three-part New Drugs on the Horizon Series at the AACR Annual Meeting 2025 wrapped up this morning. A total of 12 first-time disclosures were presented. #AACR25

[Julien Lefranc @LefrancJu]

@AggarwalLab Congrats Cris !!!!!!

[drug hunter @drughunter_com]

Molecule One-Pager: ARV-471 (vepdegestrant)

This molecule one-pager includes links to key presentations, publications, patents, preclinical and clinical PK data summaries, and more.

One-pager link: https://t.co/W4Gsc8NAZC

[Julien Lefranc @LefrancJu]

Don't forget to follow the new account @ChemEurope !

[ChemMedChem @ChemMedChem]

We are switching Social Media accounts, and we will no longer post news from this account. Please follow us on @ChemEurope

[drug hunter @drughunter_com]

BMS-986365: A Next-Generation Oral AR Heterobifunctional Degrader for Drug-Resistant Prostate Cancer

This full case study details how BMS-986365 was engineered to have low intrinsic agonism and exert direct antagonism of WT AR and more!

Full Article: https://t.co/z1pJwj81yy

[ROMERO Eugénie @eRomeroHTE]

Événement : journée thématique de la #chimie accélérée et digitalisée en R&D le 19 septembre prochain à Paris Saclay! Au programme Laurence Grimaud (@ENS_ParisSaclay ) Pascal Mieville (@EPFL), Raphaël Steimbach (@Servier), Florian Médina (@JNJNews) et bien d’autres !

[Julien Lefranc @LefrancJu]

Very nice to be back in Bristol for the CDT Summer Conference. A lot of great science presented by very talented PhD students ! Congratulations to @JonathanClayden, @VarinderAggar11 and @BCS_CDT

[Julien Lefranc @LefrancJu]

@MasurierN @SCT_asso profitez en bien !!!

[Angewandte Chemie @angew_chem]

If he could have dinner with a well-known historic figure, who would @AlexBismuto invite? @bismutolab @unibonn Find out on his #IntroducingAngewandte page https://t.co/OLDRGeDOMn https://t.co/bftFC8hxkr

[Julien Lefranc @LefrancJu]

@D_B_McConnell @Rev_Medicine @Les_Burnett indeed !!

[Julien Lefranc @LefrancJu]

I keep being amazed by the work from @Rev_Medicine Here is a example from their last patent. This work is again pushing medicinal chemistry out of out comfort zone. 6 chiral centers, 1 atropisomer , a spiro and an aziridine ! Congratulations to @Les_Burnett and all the Team!

[Julien Lefranc @LefrancJu]

Dont miss that meeting !

[Guillaume Laconde @Glaconde34]

There is still time to register for the Thematic meeting from @SCT_asso: Targeted Protein Degradation Gentilly @SanofiFR (Paris) with a fantastic program. You can click under the following link https://t.co/K4JhRcj8rk

[Guillaume Laconde @Glaconde34]

There is still time to register for the Thematic meeting from @SCT_asso: Targeted Protein Degradation Gentilly @SanofiFR (Paris) with a fantastic program. You can click under the following link https://t.co/K4JhRcj8rk

[Julien Lefranc @LefrancJu]

Check this symposium out if you haven't registered yet !

[Guillaume Laconde @Glaconde34]

@iDikic2 (Max Planck Institut of Bio)
Dr. Manfred Koegl (Boehringer Ingelheim)
Dr. Samir Jegham  (Sanofi)
Dr. Kirsten McAulay (Dundee University, CETP)
Prof. Anne-Sophie Voisin-Chiret (Caen university)

[Julien Lefranc @LefrancJu]

@VarinderAggar11 @BristolChem @BCS_CDT well done Mark !!!!!!

[Julien Lefranc @LefrancJu]

Check this out !!

[Bismuto Lab @BismutoLab]

Come and join us, what are you waiting for?! We have a fully funded PhD position @UniBonn on Sb- and Bi-luminescent compounds🧪. The deadline is April 24, interested candidate should send the application (cover letter and CV) to [email protected]

[Bismuto Lab @BismutoLab]

Come and join us, what are you waiting for?! We have a fully funded PhD position @UniBonn on Sb- and Bi-luminescent compounds🧪. The deadline is April 24, interested candidate should send the application (cover letter and CV) to [email protected]

[Guillaume Laconde @Glaconde34]

🔥🔥“TPD one-day Thematic meeting” in Paris (SANOFI) May 30th 2024 @SCT_asso : register open https://t.co/HlYneqPRGD
@DanNomura
Dr. M. Schroeder
@fmorreale_ester
Prof. N. Thomä
@iDikic2
Dr. M. Koegl
Dr. S. Jegham
Dr. K. McAulay
Prof. A.-S. Voisin-Chiret

[drug hunter @drughunter_com]

Molecules of the Month – Feb. 2024

Actelion revealed the discovery story of nivasorexant, a selective orexin-1 receptor antagonist, which completed a Ph. II clinical trial in binge-eating disorder.

Check out our other top molecules from Feb.!

Article | https://t.co/XKdteK7gqq

[Ingo Hartung @HartungIngo]

We have an open position for a postdoc in our Medicinal Chemistry & Drug Design department @merckgroup: If you are equally excited about chemistry automation and about applying synthetic chemistry to answer biological questions, check out this highly attractive opportunity!